AR113958A1 - Macrociclos a como inhibidores de pde1 - Google Patents
Macrociclos a como inhibidores de pde1Info
- Publication number
- AR113958A1 AR113958A1 ARP180103684A ARP180103684A AR113958A1 AR 113958 A1 AR113958 A1 AR 113958A1 AR P180103684 A ARP180103684 A AR P180103684A AR P180103684 A ARP180103684 A AR P180103684A AR 113958 A1 AR113958 A1 AR 113958A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- membered heteroaromatic
- bond
- phenyl
- link
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente proporciona macrociclos de fórmula (1) como inhibidores de PDE1 y su uso como un medicamento, en particular para el tratamiento de trastornos neurodegenerativos y trastornos psiquiátricos. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), en el que: el anillo A es un anillo heteroaromático de 5 ó 6 miembros o el anillo A es fenilo, y hay 1 enlace entre Y y Z; el anillo B es un anillo heteroaromático de 5 ó 6 miembros o el anillo B es fenilo, y hay 1 enlace entre V y W; cuando el anillo A es un anillo heteroaromático de 5 miembros, entonces uno de Y y Z es C y el otro es N, o Y = Z = C; cuando el anillo A es un anillo heteroaromático de 6 miembros o fenilo, entonces Y = Z = C; cuando el anillo B es un anillo heteroaromático de 5 miembros, entonces uno de V y W es C y el otro es N, o V = W = C; cuando el anillo B es un anillo heteroaromático de 6 miembros o fenilo, entonces V = W = C; el engarce es una cadena saturada de 5 - 7 miembros en el que los átomos que consisten en carbono y opcionalmente uno o más oxígenos, con la condición de que la cadena no contenga un enlace O-O, y con la condición de que el enlace a V no puede ser un enlace O-N, y con la condición de que el enlace a Y no puede ser un enlace O-N; R¹ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₄ lineal o ramificado y cicloalquilo C₃₋₄ saturado monocíclico, en el que dicho alquilo C₁₋₄ lineal o ramificado y cicloalquilo C₃₋₄ saturado monocíclico pueden estar opcionalmente sustituidos con uno o más halógeno; R² se selecciona del grupo que consiste en alquilo C₁₋₆ lineal o ramificado, cicloalquilo C₃₋₆ saturado monocíclico, oxetanilo, tetrahidrofuranilo y tetrahidropiranilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o más halógeno; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700731 | 2017-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113958A1 true AR113958A1 (es) | 2020-07-01 |
Family
ID=66815663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103684A AR113958A1 (es) | 2017-12-20 | 2018-12-17 | Macrociclos a como inhibidores de pde1 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10618913B2 (es) |
EP (1) | EP3728274B1 (es) |
JP (1) | JP7277467B2 (es) |
CN (1) | CN111491936B (es) |
AR (1) | AR113958A1 (es) |
BR (1) | BR112019017058A2 (es) |
ES (1) | ES2911398T3 (es) |
TW (1) | TW201927784A (es) |
WO (1) | WO2019121843A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
LT3723807T (lt) | 2017-12-14 | 2021-12-10 | H. Lundbeck A/S | Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1802621B1 (en) | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
AU2008224541B2 (en) | 2007-03-14 | 2013-08-22 | Sun Pharmaceutical Industries Limited | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
CN102223799A (zh) | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
CA2866302A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
TW201639851A (zh) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | 雙環咪唑衍生物 |
TW201643167A (zh) | 2015-04-22 | 2016-12-16 | H 朗德貝克公司 | 作爲pde1抑制劑之咪唑並三酮 |
JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2018
- 2018-12-11 TW TW107144517A patent/TW201927784A/zh unknown
- 2018-12-12 US US16/217,754 patent/US10618913B2/en active Active
- 2018-12-17 AR ARP180103684A patent/AR113958A1/es unknown
- 2018-12-19 ES ES18829339T patent/ES2911398T3/es active Active
- 2018-12-19 JP JP2020533776A patent/JP7277467B2/ja active Active
- 2018-12-19 EP EP18829339.3A patent/EP3728274B1/en active Active
- 2018-12-19 CN CN201880082420.5A patent/CN111491936B/zh active Active
- 2018-12-19 BR BR112019017058A patent/BR112019017058A2/pt not_active IP Right Cessation
- 2018-12-19 WO PCT/EP2018/085728 patent/WO2019121843A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2911398T3 (es) | 2022-05-19 |
WO2019121843A1 (en) | 2019-06-27 |
EP3728274B1 (en) | 2022-03-02 |
CN111491936B (zh) | 2023-07-04 |
BR112019017058A2 (pt) | 2020-04-14 |
CN111491936A (zh) | 2020-08-04 |
EP3728274A1 (en) | 2020-10-28 |
TW201927784A (zh) | 2019-07-16 |
JP2021506868A (ja) | 2021-02-22 |
US10618913B2 (en) | 2020-04-14 |
US20190185489A1 (en) | 2019-06-20 |
JP7277467B2 (ja) | 2023-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113958A1 (es) | Macrociclos a como inhibidores de pde1 | |
CO2019003349A2 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
CL2018002410A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
AR107519A1 (es) | Compuestos de piperidina sustituido y su uso | |
CR20150509A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
CR20180323A (es) | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 | |
CO2019010804A2 (es) | Derivados de indol n–sustituidos | |
UY36743A (es) | Nuevos 3-fenil-pirrolidin-2,4-diona alquinil-sustuidos y sus usos como herbicidas | |
BR112017008176A2 (pt) | método de preparação do carbonato de ácido glicérico. | |
AR104342A1 (es) | Compuesto heterocíclico | |
UY36195A (es) | Amidas de benzoxazinona como reguladores del receptor mineralocorticoide | |
CO2018004573A2 (es) | Derivados de fenilo como agonistas del receptor 2 de cannabinoides | |
SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
AR100821A1 (es) | Pirazolil-triazolil-piridinas como agentes plaguicidas | |
AR104539A1 (es) | Compuestos cíclicos | |
EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
AR107163A1 (es) | Inhibidores de quinasa |